PMID- 18448999
OWN - NLM
STAT- MEDLINE
DCOM- 20080703
LR  - 20181201
IS  - 1556-1380 (Electronic)
IS  - 1556-0864 (Linking)
VI  - 3
IP  - 5
DP  - 2008 May
TI  - Impact of HER2 gene and protein status on the treatment outcome of 
      cisplatin-based chemoradiotherapy for locally advanced non-small cell lung 
      cancer.
PG  - 477-82
LID - 10.1097/JTO.0b013e31816e2ea3 [doi]
AB  - BACKGROUND: It has not been fully evaluated whether both HER2 gene copy number 
      and HER2 protein expression are related to the outcome of chemoradiotherapy in 
      patients with locally advanced non-small cell lung cancer (LA-NSCLC). The aim of 
      this study was to evaluate their relationships. METHODS: HER2 gene copy number 
      determined by fluorescence in situ hybridization (FISH) and HER2 protein 
      expression determined by immunohistochemistry (IHC) were assessed in 68 patients 
      with LA-NSCLC enrolled in our previous phase II trials of concurrent 
      cisplatin-based chemoradiotherapy, and a multivariate analysis was conducted for 
      response and survival. RESULTS: HER2-IHC-positive tumors were detected in 23 
      patients (34%), and the median ratio of HER2 to chromosome 17 copy number was 
      0.93 (range, 0.55-2.00). The HER2-FISH results were marginally correlated with 
      the IHC results (p = 0.0715). When the median ratio in the FISH analysis was used 
      as a cut-off level for its positivity, there was no association between either 
      HER2-FISH or IHC status and objective response to chemoradiotherapy. Contrary, a 
      multivariate analysis revealed HER2-FISH result but not IHC result was an 
      independent poor prognostic factor for both overall survival and progression-free 
      survival (hazard ratio = 2.568, 95% confidence interval [CI] = 1.117-5.903, p = 
      0.0264 and hazard ratio = 2.283, 95% CI = 1.005-5.189, p = 0.0487, respectively). 
      CONCLUSIONS: Patients with HER2 FISH-positive LA-NSCLC had a poorer outcome even 
      when treated with cisplatin-based chemoradiotherapy, despite the strong need for 
      validation assessment of these observations. Development of more effective 
      treatment for these high-risk patients is needed to improve their poor prognosis.
FAU - Kuyama, Shoichi
AU  - Kuyama S
AD  - Department of Hematology, Oncology and Respiratory Medicine, Okayama University 
      Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
FAU - Hotta, Katsuyuki
AU  - Hotta K
FAU - Tabata, Masahiro
AU  - Tabata M
FAU - Segawa, Yoshihiko
AU  - Segawa Y
FAU - Fujiwara, Yoshiro
AU  - Fujiwara Y
FAU - Takigawa, Nagio
AU  - Takigawa N
FAU - Kiura, Katsuyuki
AU  - Kiura K
FAU - Ueoka, Hiroshi
AU  - Ueoka H
FAU - Eguchi, Kenji
AU  - Eguchi K
FAU - Tanimoto, Mitsune
AU  - Tanimoto M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Thorac Oncol
JT  - Journal of thoracic oncology : official publication of the International 
      Association for the Study of Lung Cancer
JID - 101274235
RN  - 0 (HER2(776-788))
RN  - 0 (Peptide Fragments)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*genetics/*metabolism/radiotherapy
MH  - *Chromosomes, Human, Pair 17
MH  - Cisplatin/*administration & dosage
MH  - Data Interpretation, Statistical
MH  - Docetaxel
MH  - Female
MH  - Gene Dosage
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*drug therapy/*genetics/*metabolism/radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*metabolism
MH  - Prognosis
MH  - Receptor, ErbB-2/*metabolism
MH  - Survival Rate
MH  - Taxoids/administration & dosage
MH  - Treatment Outcome
EDAT- 2008/05/02 09:00
MHDA- 2008/07/04 09:00
CRDT- 2008/05/02 09:00
PHST- 2008/05/02 09:00 [pubmed]
PHST- 2008/07/04 09:00 [medline]
PHST- 2008/05/02 09:00 [entrez]
AID - S1556-0864(15)31456-8 [pii]
AID - 10.1097/JTO.0b013e31816e2ea3 [doi]
PST - ppublish
SO  - J Thorac Oncol. 2008 May;3(5):477-82. doi: 10.1097/JTO.0b013e31816e2ea3.